Ernexa Therapeutics (ERNAW) Non Operating Income (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Non Operating Income of $44000.0 for Q1 2026, up 132.59% on a YoY basis from $18917.2 in Q1 2025, and down 91.7% quarter-over-quarter from $530000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Non Operating Income (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Non Operating Income for 17 years, with the latest figure at $44000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 132.59% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $445000.0 (down 43.74% YoY), and the FY2025 full-year result was -$4.8 million, down 6971.43% from the prior year.
- Non Operating Income for Q1 2026 stood at $44000.0, down from $530000.0 in the prior quarter.
- The five-year high for Non Operating Income was $25.9 million in Q4 2024, with the low at -$24.3 million in Q3 2024.
- Historically, Non Operating Income has averaged $507117.6 across 5 years, with a median of -$6000.0 in 2025.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 47745.45% — and 2024, when it plunged 2433200.0%.
- Ernexa Therapeutics' Non Operating Income stood at $288000.0 in 2022, then slumped by 236.11% to -$392000.0 in 2023, then surged by 6695.41% to $25.9 million in 2024, then sank by 97.95% to $530000.0 in 2025, then tumbled by 91.7% to $44000.0 in 2026.
- The last three Non Operating Income figures came in at $44000.0 (Q1 2026), $530000.0 (Q4 2025), and -$6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Ernexa Therapeutics | - | - | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 530,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Dec 31, 2024 | 25.85 Mn |
| Sep 30, 2024 | -24.33 Mn |
| Jun 30, 2024 | -595,000.00 |
| Mar 31, 2024 | -856,000.00 |
| Dec 31, 2023 | -392,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Mar 31, 2023 | -95,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 993,000.00 |
| Jun 30, 2022 | 10.48 Mn |
| Mar 31, 2022 | -3.08 Mn |
| Dec 31, 2021 | 634,000.00 |
| Sep 30, 2021 | 290,000.00 |
| Jun 30, 2021 | -22,000.00 |